QuiremScout™ superior in predicting intrahepatic dose distribution

In their study, Smits et al. showed that QuiremScout is a superior predictor of  intrahepatic dose distribution compared to Tech-99m-MAA. The results of their study were published online on the 9th of August 2019 in the European Journal of Nuclear Medicine and Molecular Imaging. With individualized treatment planning becoming increasingly important for patients who are selected for Selective Internal Radiation Therapy (SIRT), accurate pre-treatment activity planning is essential in order to improve the clinical benefit of the therapy.

More accurate pre-treatment activity planning requires to account for each patient’s specific intrahepatic dose distribution. However, as indicated in a number of scientific papers, the widely used Tech-99m-MAA has limited predictive value. This study shows that QuiremScout is able to more accurately predict intrahepatic dose distribution, and as such may serve as a predictive “biomarker” for a safe and more effective SIRT treatment.

“Previous studies already demonstrated that QuiremScout is safe in this population and moreover a better predictor for lung shunting than Tech-99m-MAA. As a result, QuiremScout allows for more accurate SIRT patient selection. Now, our study shows the potential of QuiremScout to also improve the efficacy of SIRT, by allowing a more accurate and truly personalized pre-treatment activity planning.” says Maarten Smits MD PhD, first author of the article.

QuiremScout is used for screening of patients that are candidates for SIRT. QuiremScout is unique, as it is the only CE-marked product on the market for that purpose.

QuiremSpheres is the only commercially available SIRT product that contains holmium-166 microspheres. Unlike the widely adopted Yttrium-90 microspheres, holmium-166 microspheres can be visualized in low concentrations by means of Single Photon Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI). This allows clinicians to quantitatively assess the distribution of microspheres in the liver, enabling accurate evaluation of treatment directly after the radio-embolization procedure.

The full article can be accessed online: DOI: 10.1007/s00259-019-04460-y

Share this post

Necessary cookies help make a website more usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

Enable

Statistical cookies help us understand how visitors use the website by collecting and reporting data anonymously. These cookies therefore do not collect any personal data from visitors.

Cookies are small text files that can be used by websites to make user experiences more efficient. By law, we may store cookies on your device if they are strictly necessary for the use of the website. These are the functional cookies. We need your consent for all other types of cookies. These cookies are named as: preferences and statistics and you do not have to accept them. This website uses different types of cookies. Some cookies are placed by third party services that are displayed on our pages.

This website uses cookies to improve your experience. You can manage your options here.